04:45 PM EDT, 03/26/2026 (MT Newswires) -- Zentalis Pharmaceuticals ( ZNTL ) late Thursday reported a 2025 loss of $1.91 per diluted share, narrowing from a loss of $2.33 a year earlier.
Analysts surveyed by FactSet expected loss of $1.82.
As of Dec. 31, the company said it had $245.9 million in cash, cash equivalents and marketable securities, with projected cash runway into late 2027.